APO Research
Talk to an analyst

APO RESEARCH · REPORT

Respiratory Syncytial Virus Vaccine for Children

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Respiratory Syncytial Virus Vaccine for Children Market Outlook and Growth Opportunities 2026

27 December 2025196 pages

Choose your research edition.

Industry ResearchRespiratory Syncytial Virus Vaccine for Children Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Respiratory Syncytial Virus Vaccine for Children Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Respiratory Syncytial Virus Vaccine for Children Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Respiratory Syncytial Virus Vaccine for Children Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Respiratory Syncytial Virus Vaccine for Children Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Respiratory Syncytial Virus Vaccine for Children market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Respiratory Syncytial Virus Vaccine for Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Respiratory Syncytial Virus Vaccine for Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Respiratory Syncytial Virus Vaccine for Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Respiratory Syncytial Virus Vaccine for Children market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Respiratory Syncytial Virus Vaccine for Children market include Clover Biopharma, Advaccine, Wits Health Consortium (Pty) Ltd, Sanofi, Pfizer, Novavax, Moderna, Meissa and Codagenix, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Respiratory Syncytial Virus Vaccine for Children market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Respiratory Syncytial Virus Vaccine for Children and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Respiratory Syncytial Virus Vaccine for Children sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Syncytial Virus Vaccine for Children market size, projected growth trends, production technologies, key applications, and end-use industries.

Respiratory Syncytial Virus Vaccine for Children Segment by Company

Clover Biopharma

Advaccine

Wits Health Consortium (Pty) Ltd

Sanofi

Pfizer

Novavax

Moderna

Meissa

Codagenix

Blue Lake Biotechnology

Respiratory Syncytial Virus Vaccine for Children Segment by Type

Recombinant Protein Vaccine

Nucleic Acid Vaccine

Others

Respiratory Syncytial Virus Vaccine for Children Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Respiratory Syncytial Virus Vaccine for Children Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Respiratory Syncytial Virus Vaccine for Children status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Respiratory Syncytial Virus Vaccine for Children market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Respiratory Syncytial Virus Vaccine for Children significant trends, drivers, influence factors in global and regions.

6. To analyze Respiratory Syncytial Virus Vaccine for Children competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for Children market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for Children and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for Children.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Respiratory Syncytial Virus Vaccine for Children market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Respiratory Syncytial Virus Vaccine for Children industry.

Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for Children manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Respiratory Syncytial Virus Vaccine for Children in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Respiratory Syncytial Virus Vaccine for Children in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Respiratory Syncytial Virus Vaccine for Children Industry Trends Table 2. Respiratory Syncytial Virus Vaccine for Children Industry Drivers Table 3. Respiratory Syncytial Virus Vaccine for Children Industry Opportunities and Challenges Table 4. Respiratory Syncytial Virus Vaccine for Children Industry Restraints Table 5. Global Respiratory Syncytial Virus Vaccine for Children Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Respiratory Syncytial Virus Vaccine for Children Revenue Share by Company (2021-2026) Table 7. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Company (Units) & (2021-2026) Table 8. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Company (2021-2026) Table 9. Global Respiratory Syncytial Virus Vaccine for Children Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Respiratory Syncytial Virus Vaccine for Children Company Ranking, (2024-2026) & (USD Million) Table 11. Global Respiratory Syncytial Virus Vaccine for Children Key Company Manufacturing Base & Headquarters Table 12. Global Respiratory Syncytial Virus Vaccine for Children Company, Product Type & Application Table 13. Global Respiratory Syncytial Virus Vaccine for Children Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Respiratory Syncytial Virus Vaccine for Children by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Recombinant Protein Vaccine Table 18. Significant Companies of Nucleic Acid Vaccine Table 19. Significant Companies of Others Table 20. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Type 2021 VS 2025 VS 2032 (Units) Table 21. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Type (2021-2026) & (Units) Table 22. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Type (2027-2032) & (Units) Table 23. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Type (2021-2026) Table 24. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Type (2027-2032) Table 25. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type (2021-2026) Table 29. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospital Table 31. Significant Companies of Centers for Disease Control and Prevention Table 32. Significant Companies of Others Table 33. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Application 2021 VS 2025 VS 2032 (Units) Table 34. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Application (2021-2026) & (Units) Table 35. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Application (2027-2032) & (Units) Table 36. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Application (2021-2026) Table 37. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Application (2027-2032) Table 38. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application (2021-2026) Table 42. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application (2027-2032) Table 43. Global Respiratory Syncytial Virus Vaccine for Children Sales by Region: 2021 VS 2025 VS 2032 (Units) Table 44. Global Respiratory Syncytial Virus Vaccine for Children Sales by Region (2021-2026) & (Units) Table 45. Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Region (2021-2026) Table 46. Global Respiratory Syncytial Virus Vaccine for Children Sales by Region (2027-2032) & (Units) Table 47. Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Region (2027-2032) Table 48. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Region (2021-2026) Table 51. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Region (2027-2032) Table 53. Global Respiratory Syncytial Virus Vaccine for Children Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Respiratory Syncytial Virus Vaccine for Children Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Respiratory Syncytial Virus Vaccine for Children Sales by Country: 2021 VS 2025 VS 2032 (Units) Table 56. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2026) & (Units) Table 58. Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Country (2021-2026) Table 59. Global Respiratory Syncytial Virus Vaccine for Children Sales by Country (2027-2032) & (Units) Table 60. Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Country (2027-2032) Table 61. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Market Share by Country (2021-2026) Table 63. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Market Share by Country (2027-2032) Table 65. Clover Biopharma Company Information Table 66. Clover Biopharma Business Overview Table 67. Clover Biopharma Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Clover Biopharma Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 69. Clover Biopharma Recent Development Table 70. Advaccine Company Information Table 71. Advaccine Business Overview Table 72. Advaccine Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Advaccine Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 74. Advaccine Recent Development Table 75. Wits Health Consortium (Pty) Ltd Company Information Table 76. Wits Health Consortium (Pty) Ltd Business Overview Table 77. Wits Health Consortium (Pty) Ltd Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Wits Health Consortium (Pty) Ltd Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 79. Wits Health Consortium (Pty) Ltd Recent Development Table 80. Sanofi Company Information Table 81. Sanofi Business Overview Table 82. Sanofi Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Sanofi Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 84. Sanofi Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pfizer Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 89. Pfizer Recent Development Table 90. Novavax Company Information Table 91. Novavax Business Overview Table 92. Novavax Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Novavax Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 94. Novavax Recent Development Table 95. Moderna Company Information Table 96. Moderna Business Overview Table 97. Moderna Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Moderna Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 99. Moderna Recent Development Table 100. Meissa Company Information Table 101. Meissa Business Overview Table 102. Meissa Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Meissa Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 104. Meissa Recent Development Table 105. Codagenix Company Information Table 106. Codagenix Business Overview Table 107. Codagenix Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Codagenix Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 109. Codagenix Recent Development Table 110. Blue Lake Biotechnology Company Information Table 111. Blue Lake Biotechnology Business Overview Table 112. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for Children Sales (Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for Children Product Portfolio Table 114. Blue Lake Biotechnology Recent Development Table 115. Key Raw Materials Table 116. Raw Materials Key Suppliers Table 117. Respiratory Syncytial Virus Vaccine for Children Distributors List Table 118. Respiratory Syncytial Virus Vaccine for Children Customers List Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Respiratory Syncytial Virus Vaccine for Children Product Image Figure 2. Global Respiratory Syncytial Virus Vaccine for Children Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032) & (US$ Million) Figure 4. Global Respiratory Syncytial Virus Vaccine for Children Sales (2021-2032) & (Units) Figure 5. Global Respiratory Syncytial Virus Vaccine for Children Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Respiratory Syncytial Virus Vaccine for Children Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Recombinant Protein Vaccine Image Figure 10. Nucleic Acid Vaccine Image Figure 11. Others Image Figure 12. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Type (2021 VS 2025 VS 2032) & (Units) Figure 13. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Type (2021-2032) Figure 15. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Centers for Disease Control and Prevention Image Figure 20. Others Image Figure 21. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Application (2021 VS 2025 VS 2032) & (Units) Figure 22. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Application (2021-2032) Figure 24. Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application (2021-2032) Figure 27. Global Respiratory Syncytial Virus Vaccine for Children Sales by Region: 2021 VS 2025 VS 2032 (Units) Figure 28. Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032) & (US$ Million) Figure 32. North America Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032) & (US$ Million) Figure 38. South America Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Respiratory Syncytial Virus Vaccine for Children Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Respiratory Syncytial Virus Vaccine for Children Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Recombinant Protein Vaccine
  • Nucleic Acid Vaccine
  • Others
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • Clover Biopharma
  • Advaccine
  • Wits Health Consortium (Pty) Ltd
  • Sanofi
  • Pfizer
  • Novavax
  • Moderna
  • Meissa
  • Codagenix
  • Blue Lake Biotechnology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032)
  4. 1.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume (2021-2032)
  5. 1.2.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Respiratory Syncytial Virus Vaccine for Children Market Dynamics
  1. 2.1 Respiratory Syncytial Virus Vaccine for Children Industry Trends
  2. 2.2 Respiratory Syncytial Virus Vaccine for Children Industry Drivers
  3. 2.3 Respiratory Syncytial Virus Vaccine for Children Industry Opportunities and Challenges
  4. 2.4 Respiratory Syncytial Virus Vaccine for Children Industry Restraints
3 Respiratory Syncytial Virus Vaccine for Children Market by Company
  1. 3.1 Global Respiratory Syncytial Virus Vaccine for Children Company Revenue Ranking in 2025
  2. 3.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Company (2021-2026)
  3. 3.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Company (2021-2026)
  4. 3.4 Global Respiratory Syncytial Virus Vaccine for Children Average Price by Company (2021-2026)
  5. 3.5 Global Respiratory Syncytial Virus Vaccine for Children Company Ranking (2024-2026)
  6. 3.6 Global Respiratory Syncytial Virus Vaccine for Children Company Manufacturing Base and Headquarters
  7. 3.7 Global Respiratory Syncytial Virus Vaccine for Children Company Product Type and Application
  8. 3.8 Global Respiratory Syncytial Virus Vaccine for Children Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Respiratory Syncytial Virus Vaccine for Children Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Respiratory Syncytial Virus Vaccine for Children Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Respiratory Syncytial Virus Vaccine for Children Market by Type
  1. 4.1 Respiratory Syncytial Virus Vaccine for Children Type Introduction
  2. 4.1.1 Recombinant Protein Vaccine
  3. 4.1.2 Nucleic Acid Vaccine
  4. 4.1.3 Others
  5. 4.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Type
  6. 4.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Type
  10. 4.3.1 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Type (2021-2032)
  12. 4.3.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type (2021-2032)
5 Respiratory Syncytial Virus Vaccine for Children Market by Application
  1. 5.1 Respiratory Syncytial Virus Vaccine for Children Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Centers for Disease Control and Prevention
  4. 5.1.3 Others
  5. 5.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Application
  6. 5.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Application
  10. 5.3.1 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Application (2021-2032)
  12. 5.3.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application (2021-2032)
6 Respiratory Syncytial Virus Vaccine for Children Regional Sales and Value Analysis
  1. 6.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region (2021-2032)
  3. 6.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region: 2021-2026
  4. 6.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region (2027-2032)
  5. 6.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Region (2021-2032)
  7. 6.4.1 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Region: 2021-2026
  8. 6.4.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Region (2027-2032)
  9. 6.5 Global Respiratory Syncytial Virus Vaccine for Children Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032)
  12. 6.6.2 North America Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032)
  15. 6.7.2 Europe Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032)
  21. 6.9.2 South America Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for Children Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Country, 2025 VS 2032
7 Respiratory Syncytial Virus Vaccine for Children Country-level Sales and Value Analysis
  1. 7.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
  4. 7.3.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2026)
  5. 7.3.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Country (2027-2032)
  6. 7.4 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Country (2021-2032)
  7. 7.4.1 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Country (2021-2026)
  8. 7.4.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Respiratory Syncytial Virus Vaccine for Children Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Respiratory Syncytial Virus Vaccine for Children Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Clover Biopharma
  2. 8.1.1 Clover Biopharma Company Information
  3. 8.1.2 Clover Biopharma Business Overview
  4. 8.1.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  6. 8.1.5 Clover Biopharma Recent Developments
  7. 8.2 Advaccine
  8. 8.2.1 Advaccine Company Information
  9. 8.2.2 Advaccine Business Overview
  10. 8.2.3 Advaccine Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Advaccine Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  12. 8.2.5 Advaccine Recent Developments
  13. 8.3 Wits Health Consortium (Pty) Ltd
  14. 8.3.1 Wits Health Consortium (Pty) Ltd Company Information
  15. 8.3.2 Wits Health Consortium (Pty) Ltd Business Overview
  16. 8.3.3 Wits Health Consortium (Pty) Ltd Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Wits Health Consortium (Pty) Ltd Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  18. 8.3.5 Wits Health Consortium (Pty) Ltd Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Novavax
  32. 8.6.1 Novavax Company Information
  33. 8.6.2 Novavax Business Overview
  34. 8.6.3 Novavax Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Novavax Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  36. 8.6.5 Novavax Recent Developments
  37. 8.7 Moderna
  38. 8.7.1 Moderna Company Information
  39. 8.7.2 Moderna Business Overview
  40. 8.7.3 Moderna Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Moderna Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  42. 8.7.5 Moderna Recent Developments
  43. 8.8 Meissa
  44. 8.8.1 Meissa Company Information
  45. 8.8.2 Meissa Business Overview
  46. 8.8.3 Meissa Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Meissa Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  48. 8.8.5 Meissa Recent Developments
  49. 8.9 Codagenix
  50. 8.9.1 Codagenix Company Information
  51. 8.9.2 Codagenix Business Overview
  52. 8.9.3 Codagenix Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Codagenix Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  54. 8.9.5 Codagenix Recent Developments
  55. 8.10 Blue Lake Biotechnology
  56. 8.10.1 Blue Lake Biotechnology Company Information
  57. 8.10.2 Blue Lake Biotechnology Business Overview
  58. 8.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for Children Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for Children Product Portfolio
  60. 8.10.5 Blue Lake Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Respiratory Syncytial Virus Vaccine for Children Value Chain Analysis
  2. 9.1.1 Respiratory Syncytial Virus Vaccine for Children Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Respiratory Syncytial Virus Vaccine for Children Sales Mode & Process
  6. 9.2 Respiratory Syncytial Virus Vaccine for Children Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Respiratory Syncytial Virus Vaccine for Children Distributors
  9. 9.2.3 Respiratory Syncytial Virus Vaccine for Children Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst